CDK7 and non-small cell lung carcinoma: Through this and validation with various assays, they identified that Cyclin-dependent kinase 7 (CDK7) is a driver of glucose consumption and inhibition with the CDK7 inhibitor, Milciclib, decreased glucose metabolism in non-small-cell lung cancer cells [257].